 |
|
|
| |
Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis
|
| |
| |
IDSA 2024
S. Grinspoon1, L. Fourman1, T Stanley1, D. Benkeser2, C. McGary3, R.B. Cash3
1Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, 2Emory University, Rollins School of Public Health, Atlanta, GA, USA, 3Theratechnologies Inc, Montréal, Canada
|
| |
|
|
|
|
|
